AR103566A1 - COMPOUNDS DERIVED FROM CONDENSED HETEROARILO AND HETEROCICLO - Google Patents
COMPOUNDS DERIVED FROM CONDENSED HETEROARILO AND HETEROCICLOInfo
- Publication number
- AR103566A1 AR103566A1 ARP160100258A ARP160100258A AR103566A1 AR 103566 A1 AR103566 A1 AR 103566A1 AR P160100258 A ARP160100258 A AR P160100258A AR P160100258 A ARP160100258 A AR P160100258A AR 103566 A1 AR103566 A1 AR 103566A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- halo
- independently selected
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- -1 - CN Chemical group 0.000 abstract 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 101100439665 Arabidopsis thaliana SWI2 gene Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
- 229920002554 vinyl polymer Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente solicitud se refiere a compuestos de heteroarilo y heterociclo condensados, composiciones farmacéuticas que los comprenden, usos de los mismos y métodos para inhibir la actividad de PI₃K para tratar enfermedades inflamatorias, autoinmunes y cáncer. Reivindicación 1: Un compuesto de fórmula (1), o sus solvatos, mezcla racémica, enantiómeros, diastereómeros, tautómeros o sales farmacéuticamente aceptables de los mismos, en donde: Z¹ y Z³ son independientemente N o CH; siempre que Z¹ y Z³ no sean N simultáneamente; Z² y Z⁴ son independientemente N o C, en el cual al menos uno de Z² y Z⁴ es N; R¹ está seleccionado a partir de halo, -CN, C₃₋₆ cicloalquilo, vinilo, etinilo, fenilo, y C₁₋₆ alquilo, en donde el C₁₋₆ alquilo está opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir de halo, OH y C₁₋₆ alcoxilo; R² es C₁₋₆ alquilo opcionalmente sustituido con uno o más grupos independientemente seleccionado a partir de C₃₋₆ cicloalquilo, fenilo y heteroarilo de 5 - 7 miembros; o R² está seleccionado a partir de fenilo, C₃₋₆ cicloalquilo, heterociclo de 4 - 8 miembros, y heteroarilo de 5 - 10 miembros, cada uno de los cuales esta opcionalmente sustituido con uno o más grupos independientemente seleccionados a partir de halo, -CN, C₁₋₆ alquilo, -SRᵃ, -S(O)ₙRᵇ y C₁₋₆ alcoxilo, en donde el C₁₋₆ alquilo y el C₁₋₆ alcoxilo están cada uno opcionalmente sustituidos con uno o más halo; R³ y R⁴ están cada uno independientemente seleccionados a partir de H, C₁₋₆ alcoxilo y C₁₋₄ alquilo, en donde el C₁₋₄ alquilo está opcionalmente sustituido con uno o más -OH; R⁵ es H o un C₁₋₄ alquilo; o R³, R⁵ y los átomos a los cuales están unidos forman un anillo heterocíclico saturado o parcialmente insaturado, mono o bicíclico, de 4 - 6 miembros, que opcionalmente contiene unos 1 - 2 heteroátomos adicionales seleccionados a partir de N, O y S, que están opcionalmente sustituidos con uno o más grupos independientemente seleccionados a partir de halo y C₁₋₆ alquilo, en donde el C₁₋₆ alquilo está opcionalmente sustituido con uno o más halo; Rᵃ y Rᵇ son cada uno independientemente H o un C₁₋₆ alquilo; m es 0 1 ó 2; n es 1 ó 2; W es un resto de fórmula (2) en donde: X¹ es C(O), X² es NR⁷, y X³ es NR⁸ o CHR⁹; X¹ es S(O) o S(O)₂, X² es CH₂ o NR¹⁰, y X³ es CH₂; o X¹ es C(O), X² es CH₂, y X³ es NH, S u O; o W es la fórmulas (3) o la fórmula (4) en donde R⁶ es H, -NH₂ o -NH(C₁₋₆ alquilo); y R⁷, R⁸, R⁹, y R¹⁰ están cada uno independientemente seleccionados a partir de H, C₁₋₆ alquilo, y C₃₋₆ cicloalquilo.The present application relates to condensed heteroaryl and heterocycle compounds, pharmaceutical compositions comprising them, uses thereof and methods to inhibit PI₃K activity to treat inflammatory, autoimmune and cancer diseases. Claim 1: A compound of formula (1), or its solvates, racemic mixture, enantiomers, diastereomers, tautomers or pharmaceutically acceptable salts thereof, wherein: Z¹ and Z³ are independently N or CH; provided that Z¹ and Z³ are not N simultaneously; Z² and Z⁴ are independently N or C, in which at least one of Z² and Z⁴ is N; R¹ is selected from halo, -CN, C₃₋₆ cycloalkyl, vinyl, ethynyl, phenyl, and C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with one or more groups independently selected from halo, OH and C₁₋₆ alkoxy; R² is C₁₋₆ alkyl optionally substituted with one or more groups independently selected from C₃₋₆ 5-7 membered cycloalkyl, phenyl and heteroaryl; or R² is selected from phenyl, C₃₋₆ cycloalkyl, 4-8 membered heterocycle, and 5-10 membered heteroaryl, each of which is optionally substituted with one or more groups independently selected from halo, - CN, C₁₋₆ alkyl, -SRᵃ, -S (O) ₙRᵇ and C₁₋₆ alkoxy, wherein the C₁₋₆ alkyl and the C₁₋₆ alkoxy are each optionally substituted with one or more halo; R³ and R⁴ are each independently selected from H, C₁₋₆ alkoxy and C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is optionally substituted with one or more -OH; R⁵ is H or a C₁₋₄ alkyl; or R³, R⁵ and the atoms to which they are attached form a saturated or partially unsaturated, mono or bicyclic, 4-6 membered heterocyclic ring, which optionally contains about 1-2 additional heteroatoms selected from N, O and S, which are optionally substituted with one or more groups independently selected from halo and C₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with one or more halo; Rᵃ and Rᵇ are each independently H or a C₁₋₆ alkyl; m is 0 1 or 2; n is 1 or 2; W is a remainder of formula (2) where: X¹ is C (O), X² is NR⁷, and X³ is NR⁸ or CHR⁹; X¹ is S (O) or S (O) ₂, X² is CH₂ or NR¹⁰, and X³ is CH₂; or X¹ is C (O), X² is CH₂, and X³ is NH, S or O; or W is the formulas (3) or the formula (4) wherein R⁶ is H, -NH₂ or -NH (C₁₋₆ alkyl); and R⁷, R⁸, R⁹, and R¹⁰ are each independently selected from H, C₁₋₆ alkyl, and C₃₋₆ cycloalkyl.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109471P | 2015-01-29 | 2015-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103566A1 true AR103566A1 (en) | 2017-05-17 |
Family
ID=56542439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100258A AR103566A1 (en) | 2015-01-29 | 2016-01-29 | COMPOUNDS DERIVED FROM CONDENSED HETEROARILO AND HETEROCICLO |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR103566A1 (en) |
| TW (1) | TW201639845A (en) |
| WO (1) | WO2016119707A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180372A (en) | 2016-02-24 | 2018-09-19 | Pfizer | DERIVATIVES OF PIRAZOLO [1,5-A] PIRAZIN-4-ILO |
| JP7071389B2 (en) | 2017-03-07 | 2022-05-18 | グアンジョウ マキシノベル ファーマシューティカルズ カンパニー リミテッド | Aminopyrimidine Condensation 5-membered heterocyclic compound, its intermediate, manufacturing method, drug composition and use |
| US11254668B2 (en) | 2017-08-14 | 2022-02-22 | Pfizer Inc. | Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives |
| CN109422730B (en) * | 2017-08-27 | 2020-04-21 | 中南民族大学 | Non-natural amino acid derivatives containing azetidine skeleton and synthetic method thereof |
| JP2024521473A (en) * | 2021-06-14 | 2024-05-31 | カムクワット バイオサイエンシーズ インコーポレイテッド | Fused heteroaryl compounds useful as anticancer agents |
| US20250059183A1 (en) * | 2021-12-08 | 2025-02-20 | Shanghai Visonpharma Co., Ltd. | Pyridine[4,3-d]pyrimidine compound as tlr7/8 agonist |
| CN119365460A (en) | 2022-04-08 | 2025-01-24 | 尚医治疗有限责任公司 | Compounds that interact with Ras superfamily proteins for the treatment of cancer, inflammatory diseases, RASopathy and fibrotic diseases |
| JP2025525946A (en) | 2022-08-05 | 2025-08-07 | カムクワット バイオサイエンシーズ インコーポレイテッド | Heterocyclic compounds and uses thereof |
| WO2024055879A1 (en) * | 2022-09-16 | 2024-03-21 | 四川科伦博泰生物医药股份有限公司 | Class of fused bicyclic compounds, method for preparing same, and use thereof |
| WO2024250984A1 (en) * | 2023-06-07 | 2024-12-12 | 上海维申医药有限公司 | Antibody-drug conjugate, and pharmaceutical composition thereof, preparation therefor and use thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014015523A1 (en) * | 2012-07-27 | 2014-01-30 | Hutchison Medipharma Limited | Novel heteroaryl and heterocycle compounds, compositions and methods |
-
2016
- 2016-01-28 WO PCT/CN2016/072474 patent/WO2016119707A1/en not_active Ceased
- 2016-01-28 TW TW105102649A patent/TW201639845A/en unknown
- 2016-01-29 AR ARP160100258A patent/AR103566A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201639845A (en) | 2016-11-16 |
| WO2016119707A1 (en) | 2016-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103566A1 (en) | COMPOUNDS DERIVED FROM CONDENSED HETEROARILO AND HETEROCICLO | |
| AR087760A1 (en) | HETEROCICLILAMINAS AS PI3K INHIBITORS | |
| AR121879A2 (en) | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF SERINE/THREONINE KINASE INHIBITORS | |
| AR120338A1 (en) | PYRIDAZINONES AS PARP7 INHIBITORS | |
| AR106595A1 (en) | HETEROCYCLIC COMPOUNDS AS PI3K-g INHIBITORS | |
| AR100438A1 (en) | PIRAZOLOPIRIDINAS AND PIRAZOLOPIRIMIDINAS | |
| AR086817A1 (en) | INHIBITING COMPOUNDS OF PHOSPHODESTERASE TYPE 10A | |
| AR096979A1 (en) | DERIVATIVES OF PIRROL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR103833A1 (en) | BICYCLIC COMPOUNDS OF SULFONAMIDE KETONE | |
| AR105845A1 (en) | BICYCLIC HETEROARIL COMPOUNDS FUSED AS MODULATORS OF THE IRAK4 FUNCTION | |
| AR100033A1 (en) | COMPOUNDS AND COMPOSITIONS TO INHIBIT THE ACTIVITY OF SHP2 | |
| AR112834A1 (en) | RAPAMYCIN DERIVATIVES | |
| AR094346A1 (en) | DERIVATIVES OF AZAINDOL AS INHIBITORS OF PROTEIN KINASES | |
| AR108388A2 (en) | OXAZOL COMPOUNDS REPLACED WITH INDAZOL AS INHIBITORS OF PI3-KINASES | |
| AR099228A1 (en) | FXIA MACROCYCLIC INHIBITORS THAT HAVE HETEROCYCLIC GROUPS | |
| AR107042A1 (en) | INHIBITORS OF BRUTON TYROSINE KINASE AND METHODS OF USE | |
| PE20190656A1 (en) | TIAZOLO-PYRIDINE COMPOUNDS REPLACED AS INHIBITORS OF MALT1 | |
| AR088748A1 (en) | MACROCICLES AS INHIBITORS OF THE XIA FACTOR | |
| AR091654A1 (en) | COMPOUNDS CONTAINING BIARILO AS INVESTED AGONISTS OF ROR-g RECEIVERS | |
| AR090293A1 (en) | ARILETER-BASED KINASE INHIBITORS | |
| AR096846A1 (en) | DIHYDROCHINOXALINONES AND MODIFIED DIHYDROPIRIDOPIRAZINONES AS INHIBITORS OF BET PROTEIN | |
| AR062011A1 (en) | DERIVATIVES OF DIAZOL AND ITS COMPOSITIONS AS ITPKB INHIBITORS | |
| AR117900A1 (en) | PYRAZOLOPYRIDINES AND TRIAZOLOPYRIDINES AS A2A / A2B INHIBITORS | |
| AR103232A1 (en) | TGFbR ANTAGONISTS | |
| AR104415A1 (en) | ANTIESTROGENIC COMPOUNDS DERIVED FROM CHROMENE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |